##semicolon##
гепатоцеллюлярная карцинома, рак печени, эпидемиология, скрининг, выживаемость, заболеваемость, смертность, ВОЗ, IARC, GCO##submission.citations##
Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer 2016; 122: 3430–3446.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485–1491.
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624
International Agency for Research on Cancer/World Health Organization. Global Cancer Observatory. Cancer Today: Data visualization tools for exploring the global cancer burden in 2020. http:// gco.iarc.fr/today. Accessed 16 Dec 2021.
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67:358–380.
Yu JS, Kim KW, Kim EK, Lee JT, Yoo HS. Contrast enhancement of small hepatocellular carcinoma: usefulness of three successive early image acquisitions during multiphase dynamic MR imaging. AJR Am J Roentgenol 1999;173:597–604.
Torzilli G, Minagawa M, Takayama T, Inoue K, Hui AM, Kubota K, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999; 30:889–893.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69 (1):182–236. Erratum in: J Hepatol. 2019;70(4):817
Singal AG, Llovet JM, Yarchoan M et al (2023) AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. https:// doi. org/ 10. 1097/ HEP. 00000 00000 000466
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 28:583–705. https:// doi. org/ 10. 3350/ cm h.2022. 0294
Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370. https:// doi. org/ 10. 1007/ s12072- 017- 9799-9
Wang CH, Wey KC, Mo LR, et al. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015;16(9):3595–3604. doi:10.73 14/apjcp.2015.16.9.3595
Tanaka H. Current role of ultrasound in the diagnosis of hepatocellular carcinoma. J Med Ultrason. 2020;47(2):239–255. doi:10.1007/s10396-020-01012-y
Jia PF, Gao WP. Malignant liver cancer ultrasonic image processing and analysis based on MATLAB. Tissue Engineering Research and Clinical Rehabilitation. 2009;13(43):8523–8526. doi: 10.39 69/j.issn.1673-8225.2009.43.026
Ren FY, Piao XX, Jin AL. Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12(29): 46564659. doi:10.3748/wjg. v12.i29.4 656
Demirtas CO, Gunduz F, Tuney D, et al. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. Eur J Gastroenterol Hepatol. 2020;32(4):517–523. doi:10.1097/ MEG.0000000000001528
Terminology and Diagnostic Criteria Committee, Japan Society of Ultrasonics in Medicine. Ultrasound diagnostic criteria for hepatic tumors. J Med Ultrason. 2014; 41:113–23.
Maringhini A, Cottone M, Sciarrino E, et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci. 1988; 33:47–51.
Maturen KE, Wasnik AP, Bailey JE, et al. Posterior acoustic enhancement in hepatocellular carcinoma. J Ultrasound Med. 2011; 30:495–9.
Itai Y, Ohtomo K, Ohnishi S, et al. Ultrasonography of small hepatic tumors. Radiat Med. 1987; 5:14–9.
Choi BI, Kim CW, Han MC, et al. Sonographic characteristics of small hepatocellular carcinoma. Gastrointest Radiol. 1989; 14:255–61.
Kutami R, Nakashima Y, Nakashima O, et al. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol. 2000; 33:282–9.
Kutami R, Nakashima Y, Nakashima O, et al. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol. 2000; 33:282–9.
Higashi T, Tobe K, Asano K, et al. Ultrasonographic characteristics of small hepatocellular carcinoma. Acta Med Okayama. 1988; 42:151–7.
Yoshida T, Matsue H, Okazaki N, et al. Ultrasonographic differentiation of hepatocellular carcinoma from metastatic liver cancer. J Clin Ultrasound. 1987; 15:431–7.
Inoue T, Kudo M, Watai R, et al. Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images. J Gastroenterol. 2005; 40:1139–47.
Minami Y, Kudo M. Hepatic malignancies: correlation between sonographic findings and pat-hological features. World J Radiol. 2010; 2:249–56.
Inoue T, Hyodo T, Korenaga K, et al. Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study. J Gastroenterol. 2016; 52:144–52.
Tanaka S, Kitamura T, Imaoka S, et al. Hep-atocellular carcinoma: sonographic and histologic correlation. AJR Am J Roentgenol. 1983;140: 701–7.
Wernecke K, Henke L, Vassallo P, et al. Pathologic explanation for hypoechoic halo seen on sonograms of malignant liver tumors: an in vitro correlative study. AJR Am J Roentgenol. 1992; 159:10 11–6.
Wernecke K, Vassallo P, Bick U, et al. The distinction between benign and malignant liver tumors on sonography: value of a hypoechoic halo. AJR Am J Roentgenol. 1992; 159:1005–9.
Makuuchi M, Hasegawa H, Yamazaki S, et al. Ultrasonic characteristics of the small hepatocellular carcinoma. Ultrasound Med Biol. 1983; Suppl 2:489–91.
Tochio H, Tomita S, Kudo M, et al. The efferent blood flow of early hepatocellular carcinoma and borderline lesions: demonstration by color Doppler imaging. J Med Ultrason. 2002; 29:205–9.
Tochio H, Kudo M. Afferent and efferent vessels of premalignant and overt hepatocellular carcinoma: observation by color Doppler imaging. Intervirology. 2004; 47:144–53.
Yen H-H. Progress in the ultrasonographic microvascular imaging. J Med Ultrasound. 2018;26: 1–2.
Kudo M, Tochio H. Intranodular blood supply correlates well with biological malignancy grade determined by tumor growth rate in pathologically proven hepatocellular carcinoma. Oncology. 2008; 75:55–64.
Marelli C. Preliminary experience with NC100100, a new ultrasound contrast agent for intravenous injection. Eur Radiol. 1999;9: S343–S346346.
Albrecht T, Hoffmann CW, Schmitz SA, et al. Phase-inversion sonography during the liver-specific late phase of contrast enhancement: improved detection of liver metastases. AJR Am J Roentgenol. 2001; 176:1191–8.
Blomley MJK, Sidhu PS, Cosgrove DO, et al. Do different types of liver lesions differ in their uptake of the microbubble contrast agent SH U 508A in the late liver phase? Early Exp Radiol. 2001; 220:6 61–7.
Blomley MJK, Albrecht T, Cosgrove DO, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: early experience. Radiology. 1999; 210:409–16.
Numata K, Luo W, Morimoto M, et al. Contrast enhanced ultrasound of hepatocellular carcinoma. World J Radiol. 2010; 2:68–82.
Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology. 2004; 232:420–30.
Leen E, Ceccotti P, Kalogeropoulou C, et al. Prospective multicenter trial evaluating a novel method of characterizing focal liver lesions using contrast-enhanced sonography. Am J Roentgenol. 2006; 186:1551–9.
Nicolau C, Vilana R, Catalá V, et al. Importance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions. Am J Roentgenol. 2006; 186:158–67.
Leen E, Ceccotti P, Moug SJ, et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection? Ann Surg. 2006; 243:236–40.
Yang H, Liu G-J, Lu M-D, et al. Evaluation of the vascular architecture of hepatocellular carcinoma by micro flow imaging: pathologic correlation. J Ultrasound Med. 2007; 26:461–7.
Trillaud H, Bruel JM, Valette PJ, et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol. 2009; 15:3748–56.
Liu GJ, Xu HX, Xie XY, et al. Does the echogenicity of focal liver lesions on baseline gray-scale ultrasound interfere with the diagnostic performance of contrast-enhanced ultrasound? Eur Radiol. 2009; 19:1214–22.
Yanagisawa K, Moriyasu F, Miyahara T, et al. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol. 2007; 33:318–25.
Lim AKP, Patel N, Eckersley RJ, et al. Evidence for spleen-specific uptake of a microbubble contrast agent: a quantitative study in healthy volunteers. Radiology. 2004; 231:785–8.
Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. Am J Roentgenol. 2009;193: 86–95.
Shunichi S, Hiroko I, Fuminori M, et al. Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles. Ultrasound Med Biol. 2009;35: 1819–27.
Tang A., Cruite I., Mitchell D.G., Sirlin C.B. Hepatocellular carcinoma imaging systems: Why they exist, how they have evolved, and how they differ. Abdom. Radiol. 2018; 43:3–12. doi: 10.1007/s00 261-017-1292-3.
Kulkarni N.M., Fung A., Kambadakone A.R., Yeh B.M. Computed Tomography Techniques, Protocols, Advancements, and Future Directions in Liver Diseases. Magn. Reson. Imaging Clin. N. Am. 2021; 29:305–320. doi: 10.1016/j.mric.2021.05.002.